### ZYME
- N/A
Impact: 0

### LUN.TO
- N/A
Impact: 0

### ARQT
- Cogent Biosciences soars on strong phase III results for bezuclastinib combo and Merck reports positive HIV study and EU approval for Keytruda SC.
Impact: +35

### EFX.TO
- N/A
Impact: 0

### ARIS.TO
- N/A
Impact: 0

### KOD
- N/A
Impact: 0

### REAL
- N/A
Impact: 0

### RCUS
- N/A
Impact: 0

### RIGL
- N/A
Impact: 0

### AGX
- N/A
Impact: 0